BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 23664030)

  • 1. Risk factors for predicting the occult nodal metastasis in T1-2N0M0 NSCLC patients staged by PET/CT: potential value in the clinic.
    Li L; Ren S; Zhang Y; Guan Y; Zhao J; Liu J; Wang Q; Chen G; Chen H; Xiang J; Fu X
    Lung Cancer; 2013 Aug; 81(2):213-7. PubMed ID: 23664030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT.
    Park HK; Jeon K; Koh WJ; Suh GY; Kim H; Kwon OJ; Chung MP; Lee KS; Shim YM; Han J; Um SW
    Respirology; 2010 Nov; 15(8):1179-84. PubMed ID: 20573058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: Risk factors, pattern, and histopathological study.
    Kanzaki R; Higashiyama M; Fujiwara A; Tokunaga T; Maeda J; Okami J; Kozuka T; Hosoki T; Hasegawa Y; Takami M; Tomita Y; Kodama K
    Lung Cancer; 2011 Mar; 71(3):333-7. PubMed ID: 20619479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of occult lymph node metastasis by metabolic parameters in patients with clinically N0 esophageal squamous cell carcinoma.
    Moon SH; Kim HS; Hyun SH; Choi YS; Zo JI; Shim YM; Lee KH; Kim BT; Choi JY
    J Nucl Med; 2014 May; 55(5):743-8. PubMed ID: 24700884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for mediastinal lymph node metastasis in non-small-cell lung cancer by PET/CT.
    Xu ZQ; Xie LJ; Fan W; Duan XB; Cheng MH
    Nucl Med Commun; 2014 May; 35(5):466-71. PubMed ID: 24535381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Potential value of FDG PET-CT in predicting occult lymph node metastasis in clinical stage ⅠA lung adenocarcinoma].
    Lyu L; Liu Y; Wang XY; Zhang ZK; Tao XL; Yang L; Wu N
    Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):441-447. PubMed ID: 31216830
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases.
    Al-Sarraf N; Gately K; Lucey J; Aziz R; Doddakula K; Wilson L; McGovern E; Young V
    Eur J Cardiothorac Surg; 2008 Oct; 34(4):892-7. PubMed ID: 18722132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Kaseda K; Asakura K; Kazama A; Ozawa Y
    World J Surg; 2016 Dec; 40(12):2976-2983. PubMed ID: 27456499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of occult lymph node metastasis using SUV, volumetric parameters and intratumoral heterogeneity of the primary tumor in T1-2N0M0 lung cancer patients staged by PET/CT.
    Ouyang ML; Xia HW; Xu MM; Lin J; Wang LL; Zheng XW; Tang K
    Ann Nucl Med; 2019 Sep; 33(9):671-680. PubMed ID: 31190182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited predictive value of dual-time-point F-18 FDG PET/CT for evaluation of pathologic N1 status in NSCLC patients.
    Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK
    Clin Nucl Med; 2011 Jun; 36(6):434-9. PubMed ID: 21552019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
    Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
    J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
    Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
    Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for N2 metastasis in patients with non-small-cell lung cancer: multivariate analyses of 18F-FDG PET/CT data.
    Su M; Li Y; Li F; Li L; Tian R
    Nucl Med Commun; 2014 Sep; 35(9):916-21. PubMed ID: 24785010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-to-liver standard uptake ratio using fluorine-18 fluorodeoxyglucose positron emission tomography computed tomography effectively predict occult lymph node metastasis of non-small cell lung cancer patients.
    Shi YM; Niu R; Shao XL; Zhang FF; Shao XN; Wang JF; Wang XS; Liu B; Yu WJ; Wang YT
    Nucl Med Commun; 2020 May; 41(5):459-468. PubMed ID: 32187163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography.
    Al-Sarraf N; Aziz R; Gately K; Lucey J; Wilson L; McGovern E; Young V
    Eur J Cardiothorac Surg; 2008 Jan; 33(1):104-9. PubMed ID: 17977738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Node/aorta and node/liver SUV ratios from (18)F-FDG PET/CT may improve the detection of occult mediastinal lymph node metastases in patients with non-small cell lung carcinoma.
    Kuo WH; Wu YC; Wu CY; Ho KC; Chiu PH; Wang CW; Chang CJ; Yu CT; Yen TC; Lin C
    Acad Radiol; 2012 Jun; 19(6):685-92. PubMed ID: 22459646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.